FDAsafety guidance77% confidence
FDA AP — ARGATROBAN (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Sandoz; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA020883. Sponsor: SANDOZ. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.
Supporting Context
- Therapeutic area
- Endocrinology · GLP-1 Agonist
- Sub-indication
- General
Related signal: Sandoz Receives FDA Approval for Liraglutide ANDA212972